Clinical Trial Update: Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a pharmacogenomics IND study using Abiraterone with SNP analysis in prostate cancer, currently in Phase 2/Phase 3 and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING